Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential.

Rho kinases (ROCKs) belong to the serine-threonine family, the inhibition of which affects the function of many downstream substrates. As such, ROCK inhibitors have potential therapeutic applicability in a wide variety of pathological conditions including asthma, cancer, erectile dysfunction, glaucoma, insulin resistance, kidney failure, neuronal degeneration, and osteoporosis. To date, two ROCK inhibitors have been approved for clinical use in Japan (fasudil and ripasudil) and one in China (fasudil). In 1995 fasudil was approved for the treatment of cerebral vasospasm, and more recently, ripasudil was approved for the treatment of glaucoma in 2014. In this Perspective, we present a comprehensive review of the physiological and biological functions for ROCK, the properties and development of over 170 ROCK inhibitors as well as their therapeutic potential, the current status, and future considerations.

[1]  E. P. Kennedy,et al.  The enzymatic phosphorylation of proteins. , 1954, The Journal of biological chemistry.

[2]  Hiroko Oshima,et al.  ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles , 2005, The Journal of cell biology.

[3]  G. Novack,et al.  Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. , 2015, Ophthalmology.

[4]  M. Moskowitz,et al.  Inhibition of Rho Kinase (ROCK) Leads to Increased Cerebral Blood Flow and Stroke Protection , 2005, Stroke.

[5]  Cheuk-Man Yu,et al.  Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. , 2010, Drug discovery today.

[6]  P. Lograsso,et al.  Chroman-3-amides as potent Rho kinase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[7]  D. Newsome,et al.  Design , Synthesis , and Structure − Activity Relationships of Pyridine-Based Rho Kinase ( ROCK ) Inhibitors , 2015 .

[8]  S. Deacon,et al.  The challenge of selecting protein kinase assays for lead discovery optimization , 2008, Expert opinion on drug discovery.

[9]  Marcel L Verdonk,et al.  Group Efficiency: A Guideline for Hits‐to‐Leads Chemistry , 2008, ChemMedChem.

[10]  S. Knapp,et al.  Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery? , 2014, ACS chemical biology.

[11]  Evelien Vandewalle,et al.  AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. , 2014, Investigative ophthalmology & visual science.

[12]  Sam W. Lee,et al.  Targeted Disruption of ROCK1 Causes Insulin Resistance in Vivo* , 2009, Journal of Biological Chemistry.

[13]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[14]  Yi Xia,et al.  Synthesis and SAR of novel benzoxaboroles as a new class of β-lactamase inhibitors. , 2011, Bioorganic & medicinal chemistry letters.

[15]  K. Kaibuchi,et al.  Rho-associated Kinase Directly Induces Smooth Muscle Contraction through Myosin Light Chain Phosphorylation* , 1997, The Journal of Biological Chemistry.

[16]  K. Nakao,et al.  Genetic and Pharmacological Inhibition of Rho-associated Kinase II Enhances Adipogenesis* , 2007, Journal of Biological Chemistry.

[17]  J. Serle,et al.  Effect of 0.04% AR-13324, a ROCK, and Norepinephrine Transporter Inhibitor, on Aqueous Humor Dynamics in Normotensive Monkey Eyes , 2015, Journal of glaucoma.

[18]  Shuh Narumiya,et al.  Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension , 1997, Nature.

[19]  T. Croci,et al.  Erectile properties of the Rho-kinase inhibitor SAR407899 in diabetic animals and human isolated corpora cavernosa , 2012, Journal of Translational Medicine.

[20]  P. Jones,et al.  AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity , 2012, Clinical Cancer Research.

[21]  K. Jarnagin,et al.  Linking Phenotype to Kinase: Identification of a Novel Benzoxaborole Hinge-Binding Motif for Kinase Inhibition and Development of High-Potency Rho Kinase Inhibitors , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[22]  J. Arends,et al.  Target validation for genomics using peptide‐specific phage antibodies: A study of five gene products overexpressed in colorectal cancer , 2002, International journal of cancer.

[23]  A. Takeshita,et al.  Effects of Hydroxyfasudil Administered to the Nucleus Tractus Solitarii on Blood Pressure and Heart Rate in Spontaneously Hypertensive Rats , 2005, Clinical and experimental hypertension.

[24]  P. Lapchak,et al.  Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: Synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator , 2010, Brain Research.

[25]  M. S. Hansen,et al.  The effect of Rho-associated kinase inhibition on the ocular penetration of timolol maleate. , 2013, Investigative ophthalmology & visual science.

[26]  J. Pawlowski.  Soft Drug Strategies in Anesthesiology , 2015, International anesthesiology clinics.

[27]  N. Koizumi,et al.  Enhancement of corneal endothelium wound healing by Rho-associated kinase (ROCK) inhibitor eye drops , 2011, British Journal of Ophthalmology.

[28]  N. Goto,et al.  Wf-536 prevents tumor metastasis by inhibiting both tumor motility and angiogenic actions. , 2003, European journal of pharmacology.

[29]  S. Narumiya,et al.  Molecular Dissection of the Rho-associated Protein Kinase (p160ROCK)-regulated Neurite Remodeling in Neuroblastoma N1E-115 Cells , 1998, The Journal of cell biology.

[30]  J Schwartz,et al.  Synthesis and pharmacological properties of "soft drug" derivatives related to perhexiline. , 1988, Journal of medicinal chemistry.

[31]  G. Novack,et al.  Ocular hypotensive safety and systemic absorption of AR-13324 ophthalmic solution in normal volunteers. , 2015, American journal of ophthalmology.

[32]  P. Lograsso,et al.  Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors. , 2013, Journal of medicinal chemistry.

[33]  S. Semus,et al.  Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors. , 2007, Journal of medicinal chemistry.

[34]  Wolfram Tetzlaff,et al.  Dose-dependent beneficial and detrimental effects of ROCK inhibitor Y27632 on axonal sprouting and functional recovery after rat spinal cord injury , 2005, Experimental Neurology.

[35]  A. Shiau,et al.  Benzothiophene containing Rho kinase inhibitors: Efficacy in an animal model of glaucoma. , 2010, Bioorganic & medicinal chemistry letters.

[36]  G. Dorn,et al.  Disruption of ROCK1 gene attenuates cardiac dilation and improves contractile function in pathological cardiac hypertrophy. , 2008, Journal of molecular and cellular cardiology.

[37]  N. Bodor.  Designing safer ophthalmic drugs by soft drug approaches. , 1994, Journal of ocular pharmacology.

[38]  S. Narumiya,et al.  Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. , 2001, Investigative ophthalmology & visual science.

[39]  M. Robinson,et al.  Novel ocular antihypertensive compounds in clinical trials , 2011, Clinical ophthalmology.

[40]  P. Lograsso,et al.  Asymmetric synthesis of potent chroman-based Rho kinase (ROCK-II) inhibitors , 2011 .

[41]  H. Seo,et al.  Cardiovascular effects of a novel selective Rho kinase inhibitor, 2-(1H-indazole-5-yl)amino-4-methoxy-6-piperazino triazine (DW1865). , 2013, European journal of pharmacology.

[42]  T. Moriyama,et al.  The Rho-ROCK system as a new therapeutic target for preventing interstitial fibrosis. , 2004, Drug news & perspectives.

[43]  A. Levey,et al.  Rho Kinase II Phosphorylation of the Lipoprotein Receptor LR11/SORLA Alters Amyloid-β Production* , 2010, The Journal of Biological Chemistry.

[44]  N. Goto,et al.  WF‐536 INHIBITS METASTATIC INVASION BY ENHANCING THE HOST CELL BARRIER and INHIBITING TUMOUR CELL MOTILITY , 2003, Clinical and experimental pharmacology & physiology.

[45]  K. Fujisawa,et al.  Identification of the Rho-binding Domain of p160ROCK, a Rho-associated Coiled-coil Containing Protein Kinase* , 1996, The Journal of Biological Chemistry.

[46]  R. Pi,et al.  Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors. , 2013, European journal of medicinal chemistry.

[47]  A. Oyekan,et al.  The role of the RhoA/Rho-kinase signaling pathway in renal vascular reactivity in endothelial nitric oxide synthase null mice , 2006, Journal of hypertension.

[48]  S. Narumiya,et al.  Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. , 2000, Molecular pharmacology.

[49]  N. Bodor,et al.  Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs. , 1992, Journal of pharmaceutical sciences.

[50]  Jiang Chang,et al.  ROCK1 Deficiency Enhances Protective Effects of Antioxidants against Apoptosis and Cell Detachment , 2014, PloS one.

[51]  H. Ahmadieh,et al.  Intravitreal fasudil combined with bevacizumab for persistent diabetic macular edema: a novel treatment. , 2013, JAMA ophthalmology.

[52]  Mindy I. Davis,et al.  Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.

[53]  K. Nakao,et al.  ROCK‐I and ROCK‐II, two isoforms of Rho‐associated coiled‐coil forming protein serine/threonine kinase in mice , 1996, FEBS letters.

[54]  Youyong Li,et al.  Advances in the development of Rho-associated protein kinase (ROCK) inhibitors. , 2013, Drug discovery today.

[55]  H. Hidaka,et al.  Development of specific Rho-kinase inhibitors and their clinical application. , 2005, Biochimica et biophysica acta.

[56]  H. Hidaka,et al.  H-series protein kinase inhibitors and potential clinical applications. , 1999, Pharmacology & therapeutics.

[57]  S. Small,et al.  Protein kinase C and rho activated coiled coil protein kinase 2 (ROCK2) modulate Alzheimer's APP metabolism and phosphorylation of the Vps10-domain protein, SorL1 , 2010, Molecular Neurodegeneration.

[58]  K. Maruyama,et al.  The novel Rho kinase (ROCK) inhibitor K-115: a new candidate drug for neuroprotective treatment in glaucoma. , 2014, Investigative ophthalmology & visual science.

[59]  J. Paick,et al.  Chronic treatment with an oral rho-kinase inhibitor restores erectile function by suppressing corporal apoptosis in diabetic rats. , 2011, The journal of sexual medicine.

[60]  J. Liao,et al.  ROCKs as therapeutic targets in cardiovascular diseases , 2005, Expert review of cardiovascular therapy.

[61]  F. Andris,et al.  The Nicotinamide Phosphoribosyltransferase: a Molecular Link between Metabolism, Inflammation, and Cancer the Key Role of Nicotinamide Phosphoribosyl- Transferase in Nicotinamide Adenine Dinucleotide Metabolism , 2022 .

[62]  M. Hou,et al.  Myosin IIa activation is crucial in breast cancer derived galectin-1 mediated tolerogenic dendritic cell differentiation. , 2014, Biochimica et biophysica acta.

[63]  M. Araie,et al.  Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. , 2008, Archives of ophthalmology.

[64]  P. Lograsso,et al.  Discovery of Potent and Selective Urea-Based ROCK Inhibitors and Their Effects on Intraocular Pressure in Rats. , 2010, ACS medicinal chemistry letters.

[65]  Yoshiharu Matsuura,et al.  Phosphorylation and Activation of Myosin by Rho-associated Kinase (Rho-kinase)* , 1996, The Journal of Biological Chemistry.

[66]  P. Lograsso,et al.  The development of benzimidazoles as selective rho kinase inhibitors. , 2010, Bioorganic & Medicinal Chemistry Letters.

[67]  J. Sosman,et al.  Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  S. Narumiya,et al.  A Critical Role for a Rho-Associated Kinase, p160ROCK, in Determining Axon Outgrowth in Mammalian CNS Neurons , 2000, Neuron.

[69]  I. Pang,et al.  Acute effects of glaucoma medications on rat intraocular pressure. , 2005, Experimental eye research.

[70]  Toshihiro Inoue,et al.  Intra‐ocular pressure‐lowering effects of a Rho kinase inhibitor, ripasudil (K‐115), over 24 hours in primary open‐angle glaucoma and ocular hypertension: a randomized, open‐label, crossover study , 2015, Acta ophthalmologica.

[71]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[72]  W. Guida,et al.  Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). , 2012, MedChemComm.

[73]  Brion W. Murray,et al.  Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors , 2012, Proceedings of the National Academy of Sciences.

[74]  Chadwick M. Hales,et al.  Pharmacologic Inhibition of ROCK2 Suppresses Amyloid-β Production in an Alzheimer's Disease Mouse Model , 2013, The Journal of Neuroscience.

[75]  S. Narumiya,et al.  ROCK‐I and ROCK‐II cooperatively regulate closure of eyelid and ventral body wall in mouse embryo , 2005, Genes to cells : devoted to molecular & cellular mechanisms.

[76]  P. Lograsso,et al.  Benzimidazole- and benzoxazole-based inhibitors of Rho kinase. , 2008, Bioorganic & medicinal chemistry letters.

[77]  Helmut Mack,et al.  Rho kinase, a promising drug target for neurological disorders , 2005, Nature Reviews Drug Discovery.

[78]  B. Dahal,et al.  Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension , 2010, European Respiratory Journal.

[79]  T. Bisogno,et al.  Metabolically labile cannabinoid esters: a 'soft drug' approach for the development of cannabinoid-based therapeutic drugs. , 2007, Bioorganic & medicinal chemistry letters.

[80]  Yan Liu,et al.  Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities , 2013, Oncogene.

[81]  C. M. Hansen,et al.  Cyanoguanidine CHS 828 induces programmed cell death with apoptotic features in human breast cancer cells in vitro. , 2000, Anticancer research.

[82]  P. Lograsso,et al.  Detection of myosin light chain phosphorylation--a cell-based assay for screening Rho-kinase inhibitors. , 2008, Biochemical and biophysical research communications.

[83]  D. Behm,et al.  Novel Rho Kinase Inhibitors with Anti-inflammatory and Vasodilatory Activities , 2007, Journal of Pharmacology and Experimental Therapeutics.

[84]  M. Araie,et al.  Efficacy and safety of SNJ‐1656 in primary open‐angle glaucoma or ocular hypertension , 2015, Acta ophthalmologica.

[85]  N. Bodor,et al.  Ophthalmic drug design based on the metabolic activity of the eye: Soft drugs and chemical delivery systems , 2005, The AAPS Journal.

[86]  N. Waters,et al.  Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension. , 2014, Bioorganic & medicinal chemistry letters.

[87]  D. Lesieur,et al.  Rho-kinase Inhibitors: Pharmacomodulations on the Lead Compound Y-32885 , 2002, Journal of enzyme inhibition and medicinal chemistry.

[88]  Alex Matter,et al.  Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.

[89]  José L Medina-Franco,et al.  Activity Cliffs: Facts or Artifacts? , 2013, Chemical biology & drug design.

[90]  Ying Sun,et al.  RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. , 2012, Cancer research.

[91]  F. Giancotti,et al.  Molecular characterization of the tumor-suppressive function of nischarin in breast cancer. , 2011, Journal of the National Cancer Institute.

[92]  Lumin Zhang,et al.  ROCK1 plays an essential role in the transition from cardiac hypertrophy to failure in mice. , 2010, Journal of Molecular and Cellular Cardiology.

[93]  S. Narumiya,et al.  Use and properties of ROCK-specific inhibitor Y-27632. , 2000, Methods in enzymology.

[94]  N. Bodor,et al.  Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites. , 2002, Methods in molecular biology.

[95]  C. Bourgier,et al.  Rho/ROCK pathway as a molecular target for modulation of intestinal radiation-induced toxicity. , 2007, The British journal of radiology.

[96]  A. Halayko,et al.  Rho-kinase as a drug target for the treatment of airway hyperrespon-siveness in asthma. , 2006, Mini reviews in medicinal chemistry.

[97]  Fumio Matsumura,et al.  Phosphorylation of Myosin-Binding Subunit (Mbs) of Myosin Phosphatase by Rho-Kinase in Vivo , 1999, The Journal of cell biology.

[98]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.

[99]  G. Novack.  Rho kinase inhibitors for the treatment of glaucoma , 2013, Drugs of the Future.

[100]  K. Furie,et al.  Selective ROCK2 inhibition in focal cerebral ischemia , 2013, Annals of clinical and translational neurology.

[101]  N. Koizumi,et al.  The ROCK inhibitor eye drop accelerates corneal endothelium wound healing. , 2013, Investigative ophthalmology & visual science.

[102]  N. Yoshimura,et al.  The effect of Rho-associated protein kinase inhibitor on monkey Schlemm's canal endothelial cells. , 2012, Investigative ophthalmology & visual science.

[103]  H. Quigley,et al.  The number of people with glaucoma worldwide in 2010 and 2020 , 2006, British Journal of Ophthalmology.

[104]  Y. Shimizu,et al.  Alleviating effects of AS1892802, a Rho kinase inhibitor, on osteoarthritic disorders in rodents. , 2011, Journal of pharmacological sciences.

[105]  S. Antoniu.  Targeting RhoA/ROCK pathway in pulmonary arterial hypertension , 2012, Expert opinion on therapeutic targets.

[106]  M. Araie,et al.  Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. , 2013, American journal of ophthalmology.

[107]  R. Rettig,et al.  The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries , 2012, Journal of hypertension.

[108]  Fan-hong Wu,et al.  A metal-free and recyclable synthesis of benzothiazoles using thiourea as a sulfur surrogate , 2015 .

[109]  Hiroaki Kume,et al.  RhoA/Rho-kinase as a therapeutic target in asthma. , 2008, Current medicinal chemistry.

[110]  Muriel Hachet-Haas,et al.  An Antedrug of the CXCL12 Neutraligand Blocks Experimental Allergic Asthma without Systemic Effect in Mice , 2013, The Journal of Biological Chemistry.

[111]  J. Kira,et al.  The selective Rho-kinase inhibitor Fasudil is protective and therapeutic in experimental autoimmune encephalomyelitis , 2006, Journal of Neuroimmunology.

[112]  Jia Liu,et al.  Fasudil, a Rho-Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice , 2012, International journal of molecular sciences.

[113]  J. Medina-Franco,et al.  Docking of Protein Kinase B Inhibitors: Implications in the Structure‐Based Optimization of a Novel Scaffold , 2010, Chemical biology & drug design.

[114]  Taebo Sim,et al.  Discovery of potent and selective covalent inhibitors of JNK. , 2012, Chemistry & biology.

[115]  N. Bodor,et al.  Recent advances in the design and development of soft drugs. , 2014, Die Pharmazie.

[116]  Theonie Anastassiadis,et al.  Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity , 2011, Nature biotechnology.

[117]  Anne J. Ridley,et al.  ROCKs: multifunctional kinases in cell behaviour , 2003, Nature Reviews Molecular Cell Biology.

[118]  H. Saya,et al.  Localization of the gene coding for ROCK II/Rho kinase on human chromosome 2p24. , 1999, Genomics.

[119]  T. Lue,et al.  The future is today: emerging drugs for the treatment of erectile dysfunction , 2010, Expert opinion on emerging drugs.

[120]  P. Lograsso,et al.  Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[121]  H. Tanihara,et al.  Rho-associated kinase inhibitors: A novel glaucoma therapy , 2013, Progress in Retinal and Eye Research.

[122]  N. Koizumi,et al.  Rho-Associated Kinase Inhibitor Eye Drop Treatment as a Possible Medical Treatment for Fuchs Corneal Dystrophy , 2013, Cornea.

[123]  P. Khaw,et al.  Primary open-angle glaucoma , 2004, The Lancet.

[124]  M. Araie,et al.  Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. , 2013, JAMA ophthalmology.

[125]  P. Lograsso,et al.  Rho kinase inhibitors: a patent review (2012 – 2013) , 2014, Expert opinion on therapeutic patents.

[126]  Toshikazu Nakamura,et al.  Specific Activation of LIM kinase 2 via Phosphorylation of Threonine 505 by ROCK, a Rho-dependent Protein Kinase* , 2001, The Journal of Biological Chemistry.

[127]  J. Liao,et al.  Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. , 2011, Trends in pharmacological sciences.

[128]  N Bodor,et al.  Soft drug design: General principles and recent applications , 2000, Medicinal research reviews.

[129]  H. Hidaka,et al.  The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. , 2002, Pharmacology & therapeutics.

[130]  S. Kuroda,et al.  Synergistic effects of bone marrow stromal cells and a Rho kinase (ROCK) inhibitor, Fasudil on axon regeneration in rat spinal cord injury , 2009, Neuropathology : official journal of the Japanese Society of Neuropathology.

[131]  P. Lograsso,et al.  Synthesis and biological evaluation of 4-quinazolinones as Rho kinase inhibitors. , 2011, Bioorganic & medicinal chemistry letters.

[132]  Robert T Chang,et al.  An emerging treatment option for glaucoma: Rho kinase inhibitors , 2014, Clinical ophthalmology.

[133]  A. Kannt,et al.  End-organ protection in hypertension by the novel and selective Rho-kinase inhibitor, SAR407899. , 2015, World journal of cardiology.

[134]  Y. Furuichi,et al.  Sustained analgesic effect of the Rho kinase inhibitor AS1892802 in rat models of chronic pain. , 2010, Journal of Pharmacological Sciences.

[135]  U. Wewer,et al.  Regulation of ROCK Activity in Cancer , 2013, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[136]  H. Tanihara,et al.  Effects of Y-39983, a Selective Rho-Associated Protein Kinase Inhibitor, on Blood Flow in Optic Nerve Head in Rabbits and Axonal Regeneration of Retinal Ganglion Cells in Rats , 2011, Current eye research.

[137]  R. Mali,et al.  Role of Rho kinases in abnormal and normal hematopoiesis , 2014, Current opinion in hematology.

[138]  P. Lograsso,et al.  Rho kinase (ROCK) inhibitors and their application to inflammatory disorders. , 2009, Current topics in medicinal chemistry.

[139]  R. Vergona,et al.  Inhibition of Rho-Kinase by Hydroxyfasudil Prevents Vasopressin-Induced Myocardial Ischemia in Donryu Rats by Attenuating Coronary Vasoconstriction , 2005, Pharmacology.

[140]  P. Kaufman,et al.  H-1152 effects on intraocular pressure and trabecular meshwork morphology of rat eyes. , 2008, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[141]  M. Wax,et al.  Noninvasive measurement of rodent intraocular pressure with a rebound tonometer. , 2005, Investigative ophthalmology & visual science.

[142]  P. Lograsso,et al.  Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors. , 2008, Journal of medicinal chemistry.

[143]  J. Stasch,et al.  Design and Synthesis of Potent and Selective Azaindole‐Based Rho Kinase (ROCK) Inhibitors , 2008, ChemMedChem.

[144]  J. Kiel,et al.  Effect of AR-13324 on Episcleral Venous Pressure in Dutch Belted Rabbits , 2014, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[145]  M. Araie,et al.  Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery. , 2007, Investigative ophthalmology & visual science.

[146]  R. Pi,et al.  Simply combining fasudil and lipoic acid in a novel multitargeted chemical entity potentially useful in central nervous system disorders , 2014 .

[147]  Karly P Garnock-jones.  Ripasudil: First Global Approval , 2014, Drugs.

[148]  Yan Yin,et al.  Discovery of potent and selective urea-based ROCK inhibitors: Exploring the inhibitor's potency and ROCK2/PKA selectivity by 3D-QSAR, molecular docking and molecular dynamics simulations. , 2015, Bioorganic & medicinal chemistry.

[149]  N. Goto,et al.  Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma , 2003, Cancer Chemotherapy and Pharmacology.

[150]  P. Lograsso,et al.  Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II. , 2007, Bioorganic & medicinal chemistry letters.

[151]  P. Lograsso,et al.  Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors. , 2010, Journal of medicinal chemistry.

[152]  H. Randeva,et al.  Nuclear Factor-κB Induction by Visfatin in Human Vascular Endothelial Cells , 2008, Diabetes Care.

[153]  Marcel L Verdonk,et al.  Identification of inhibitors of protein kinase B using fragment-based lead discovery. , 2007, Journal of medicinal chemistry.

[154]  S. Semus,et al.  Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity. , 2007, Journal of medicinal chemistry.

[155]  M. Olson.  Applications for ROCK kinase inhibition. , 2008, Current opinion in cell biology.

[156]  M. Inagaki,et al.  Design and synthesis of Rho kinase inhibitors (I). , 2004, Bioorganic & medicinal chemistry.

[157]  B. Chandran,et al.  Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies , 2013, Translational Research.

[158]  D. Sriram,et al.  Design of dual inhibitors of ROCK-I and NOX2 as potential leads for the treatment of neuroinflammation associated with various neurological diseases including autism spectrum disorder. , 2015, Molecular bioSystems.

[159]  M. Fleming,et al.  The Structure of Dimeric ROCK I Reveals the Mechanism for Ligand Selectivity* , 2006, Journal of Biological Chemistry.

[160]  P. Lograsso,et al.  Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I). , 2011, Bioorganic & medicinal chemistry letters.

[161]  Sasidhar Vemula,et al.  Distinct roles for ROCK1 and ROCK2 in the regulation of cell detachment , 2013, Cell Death and Disease.

[162]  S. Narumiya,et al.  Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. , 1999, Science.

[163]  S. Xiao,et al.  Porcine Epidemic Diarrhea Virus Nucleocapsid Protein Antagonizes Beta Interferon Production by Sequestering the Interaction between IRF3 and TBK1 , 2014, Journal of Virology.

[164]  R. Pi,et al.  Fasudil and its analogs: a new powerful weapon in the long war against central nervous system disorders? , 2013, Expert opinion on investigational drugs.

[165]  D. Leysen,et al.  The effect of AMA0428, a novel and potent ROCK inhibitor, in a model of neovascular age-related macular degeneration. , 2015, Investigative ophthalmology & visual science.

[166]  John T. Powers,et al.  Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors , 2010, Nature.

[167]  J. Liao,et al.  Physiological role of ROCKs in the cardiovascular system. , 2006, American journal of physiology. Cell physiology.

[168]  J. Mestan,et al.  Allosteric inhibitors of Bcr-abl–dependent cell proliferation , 2006, Nature chemical biology.

[169]  P. Lograsso,et al.  Amino acid derived quinazolines as Rock/PKA inhibitors. , 2013, Bioorganic & medicinal chemistry letters.

[170]  H. Hidaka,et al.  Inhibition of Rho‐kinase‐induced myristoylated alanine‐rich C kinase substrate (MARCKS) phosphorylation in human neuronal cells by H‐1152, a novel and specific Rho‐kinase inhibitor , 2002, Journal of neurochemistry.

[171]  A. Kannt,et al.  Pharmacological Characterization of SAR407899, a Novel Rho-Kinase Inhibitor , 2009, Hypertension.

[172]  G. Novack,et al.  Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. , 2011, American journal of ophthalmology.

[173]  B. Bryan,et al.  Pharmacological inhibition of Rho-kinase (ROCK) signaling enhances cisplatin resistance in neuroblastoma cells. , 2010, International journal of oncology.

[174]  M. Olson,et al.  Rho‐associated kinases in tumorigenesis: re‐considering ROCK inhibition for cancer therapy , 2012, EMBO reports.

[175]  J. Pintor,et al.  Potential role of Rho-associated protein kinase inhibitors for glaucoma treatment. , 2012, Recent patents on endocrine, metabolic & immune drug discovery.

[176]  G. Novack,et al.  Ocular hypotensive efficacy, safety and systemic absorption of AR-12286 ophthalmic solution in normal volunteers , 2013, British Journal of Ophthalmology.

[177]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[178]  H. Tanihara,et al.  Rho-associated protein kinase inhibitor, Y-27632, induces alterations in adhesion, contraction and motility in cultured human trabecular meshwork cells. , 2006, Experimental eye research.

[179]  S. Semus,et al.  Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases. , 2008, Journal of medicinal chemistry.

[180]  S. Narumiya,et al.  Targeted Disruption of the Mouse Rho-Associated Kinase 2 Gene Results in Intrauterine Growth Retardation and Fetal Death , 2003, Molecular and Cellular Biology.

[181]  Hiroto Yamaguchi,et al.  Molecular mechanism for the regulation of rho-kinase by dimerization and its inhibition by fasudil. , 2006, Structure.

[182]  Michael D. Schneider,et al.  Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[183]  D. Leysen,et al.  Design, synthesis, and biological evaluation of novel, highly active soft ROCK inhibitors. , 2015, Journal of medicinal chemistry.

[184]  A. Iwashita,et al.  Antinociceptive Effects of AS1892802, a Novel Rho Kinase Inhibitor, in Rat Models of Inflammatory and Noninflammatory Arthritis , 2010, Journal of Pharmacology and Experimental Therapeutics.

[185]  J. Stasch,et al.  Cardiovascular effects of a novel potent and highly selective azaindole‐based inhibitor of Rho‐kinase , 2007, British journal of pharmacology.

[186]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[187]  T. Yamashita,et al.  Rho-ROCK inhibitors for the treatment of CNS injury. , 2007, Recent patents on CNS drug discovery.

[188]  W. Guida,et al.  Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors. , 2012, Journal of medicinal chemistry.

[189]  M. Inatani,et al.  Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. , 2007, Investigative ophthalmology & visual science.

[190]  J. Weiss,et al.  Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism , 2014, Proceedings of the National Academy of Sciences.

[191]  R. Komers,et al.  Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure. , 2011, Kidney international.

[192]  K. Kaibuchi,et al.  Structural basis for induced-fit binding of Rho-kinase to the inhibitor Y-27632. , 2006, Journal of biochemistry.

[193]  Dennis Lee,et al.  Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges , 2005, Expert opinion on therapeutic targets.

[194]  D. Leysen,et al.  3-[2-(Aminomethyl)-5-[(pyridin-4-yl)carbamoyl]phenyl] benzoates as soft ROCK inhibitors. , 2013, Bioorganic & medicinal chemistry letters.

[195]  Kozo Kaibuchi,et al.  Regulation of Myosin Phosphatase by Rho and Rho-Associated Kinase (Rho-Kinase) , 1996, Science.

[196]  J. Tesmer,et al.  Molecular Basis for Small Molecule Inhibition of G Protein-Coupled Receptor Kinases , 2014, ACS chemical biology.